Value Bridge — DANA-FARBER CANCER INSTITUTE
Current $-94M → Target $-53M (+$41.6M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-94.2M
Current EBITDA
$-52.6M
Target EBITDA
+$41.6M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$0.0M
AR Acceleration
$0.0M
Coding Accuracy Uplift
$9.4M
Payer Mix Optimization
$22.6M
Cost to Collect Reduction
$7.5M
Clean Claim Improvement
$5.7M
Volume & Rate Growth
$37.7M
What This Means
The 7-lever model projects a 0% EBITDA uplift from $-94M to $-53M. The highest-impact lever is Volume & Rate Growth at $15.1M probability-weighted.
IC talking point: "We see $42M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $458M in equity value creation."